BridgeBio Pharma BBIO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
BridgeBio Pharma (BBIO) Business Model and Operations Summary
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Key Insights
BridgeBio Pharma (BBIO) Core Market Data and Business Metrics
Latest Closing Price
$33.02Market Cap
$6.31 BillionPrice-Earnings Ratio
-11.47Total Outstanding Shares
190.19 Million SharesTotal Employees
730Dividend
No dividendIPO Date
June 27, 2019SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
3160 Porter Dr., Palo Alto, CA, 94304
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $60.78 Million |
| Net Cash Flow From Operating Activities | $-520.73 Million |
| Net Cash Flow From Operating Activities, Continuing | $-520.73 Million |
| Net Cash Flow From Investing Activities | $60.78 Million |
| Net Cash Flow From Financing Activities, Continuing | $748.46 Million |
| Net Cash Flow, Continuing | $288.51 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $-2.88 |
| Diluted Average Shares | $186.08 Million |
| Income/Loss Before Equity Method Investments | $-511.01 Million |
| Income Tax Expense/Benefit, Current | $1.15 Million |
| Income/Loss From Continuing Operations Before Tax | $-542.19 Million |
| Nonoperating Income/Loss | $50.78 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-543.37 Million |
| Other Comprehensive Income/Loss | $-23,000 |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $-7.58 Million |
| Comprehensive Income/Loss Attributable To Parent | $-535.78 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Assets | $720.69 Million |
| Equity Attributable To Noncontrolling Interest | $10.15 Million |
| Intangible Assets | $23.93 Million |
| Noncurrent Assets | $198.65 Million |
| Other Non-current Assets | $167.71 Million |
| Assets | $919.34 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||